Skip to main content

Posts

Showing posts with the label pharmaceutical sector

Featured Post

Market Daily Report: Bursa Malaysia Ends Nearly Flat As Construction Stocks Attract Buying

 KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.

Pharmaniaga Poised for PN17 Exit by Early 2026

Key Takeaway:  Pharmaniaga Bhd is on track to exit its PN17 status by  1Q2026  following a successful regularisation plan, with MBSB Research upgrading the stock to a  “buy” call  and setting a target price of  32 sen . Pharmaniaga Bhd  is expected to leave its financially distressed PN17 status by the first quarter of 2026, according to a note from  MBSB Research . The brokerage upgraded its recommendation on the stock to “buy,” citing improved fundamentals and stronger growth prospects post-regularisation. The group’s turnaround strategy included a  capital reduction and a large private placement , which brought in  19 new investors . As a result, Pharmaniaga’s issued shares ballooned from  1.441 billion to 6.557 billion , while major shareholders saw their stakes diluted from  55% to 44% . Despite the dilution, the move successfully  recapitalised the company , providing it with a stronger balance sheet and healthier ca...

Pfizer Stock Rated 'Buy' with 15% Upside and 6.8% Dividend Yield — Here's What You Need to Know

Why Analysts Like Pfizer: Pfizer is  profitable and undervalued , offering solid income through dividends and room for price growth. The stock recently broke out of a  bullish price pattern , showing momentum for further gains. Technical indicators suggest an  uptrend is in place , with the short-term average price staying above the longer-term average. Financial Outlook: Pfizer’s expected performance over the next 3 years: Year Revenue Net Profit 2025 ~$62.5 billion ~$17.2 billion 2026 ~$62.4 billion ~$17.8 billion 2027 ~$61.2 billion ~$17.8 billion Net profit margin  expected to stay strong at around  28.4% . Net profit growth  over the next 3 years is forecasted at  over 30% . What the Charts Are Saying: Pfizer’s price recently broke above a short-term resistance level. Strong buying momentum is confirmed by consistent  higher lows  and a  bullish candlestick pattern  (white Marubozu). Near-term price targets: Resistance:  $...